Related Experiment Video
Updated: Apr 7, 2026
05:35
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
Published on: June 6, 2025
2.2K
Addressing the need for repeat prostate biopsy: new technology and approaches
Michael L Blute1, E Jason Abel1, Tracy M Downs1
1Department of Urology,University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Madison, WI 53705, USA.
Nature Reviews. Urology
|July 15, 2015
Summary
No clear guidelines exist for repeat prostate cancer biopsies after an initial negative result. Elevated PSA levels complicate diagnosis, but new tests and imaging can better identify men needing further investigation.
Area of Science:
- Urology
- Oncology
- Diagnostic Medicine
Background:
- Accurate prostate cancer diagnosis is challenging after initial negative biopsy results, especially with persistently elevated PSA levels.
- Current methods like total PSA and PSA kinetics are insufficient to determine the need for repeat biopsies in these cases.
- This leads to potential unnecessary procedures for patients suspected of having prostate cancer.
Purpose of the Study:
- To address the clinical management challenge posed by negative initial prostate cancer biopsy results.
- To explore alternative strategies for identifying patients who may still have prostate cancer despite initial negative findings.
- To propose a cost-effective strategy and outline future research directions for this diagnostic dilemma.
Main Methods:
- Review of existing diagnostic challenges and limitations of current biomarkers.
- Evaluation of alternative serum PSA-related measurements for improved diagnostic accuracy.
- Consideration of advanced diagnostic tools such as MRI and novel tissue-based assays.
- Development of a proposed cost-effective strategy for patient management.
Main Results:
- Total serum PSA and PSA kinetics are ineffective indicators for repeat prostate biopsy after initial negative results.
- Alternative serum PSA-related measurements, combined with clinicopathological features, offer more sensitive and specific diagnostic potential.
- FDA-approved tests (e.g., Progensa®) and prostate MRI are viable options for risk stratification.
- Emerging tissue-based assays targeting methylation changes show promise for future diagnostics.
Conclusions:
- There is a critical need for guidelines regarding rebiopsy in patients with initial negative prostate cancer diagnoses.
- Utilizing advanced biomarkers and imaging techniques can improve the identification of at-risk individuals, reducing unnecessary biopsies.
- A comprehensive strategy combining novel diagnostics and clinical assessment is essential for effective prostate cancer management in this patient group.
